Home/Pipeline/ML1707

ML1707

Alzheimer's Disease, Frontotemporal Dementia

PreclinicalActive

Key Facts

Indication
Alzheimer's Disease, Frontotemporal Dementia
Phase
Preclinical
Status
Active
Company

About Medilabo

Medilabo develops intranasal drug delivery technology to treat neurodegenerative diseases by directly targeting the brain via the olfactory nerve.

View full company profile

Therapeutic Areas